Sponsor(s): Institute of Chinese Pharmaceutical Association
24 issues per year
Current Issue: Issue 17, 2020
Journal official website:http://zgzye.cbpt.cnki.net/WKE/WebPublication/index.aspx?mid=zgzye
China Journal of Chinese Materia Medica, the 1st in the field of TCM, is supervised by China Association for Science and Technology and sponsored by Institute of Chinese Pharmaceutical Association. The journal is China's earliest comprehensive core journal of traditional Chinese medicine, and always maintains the circulation top in the professional areas. The journal publishes the latest research and progress of traditional Chinese medicine and takes a leading position in numbers of articles published, downloads and citations among all journals in this discipline. Its scope covers new achievements, technologies, methods, experiences and concepts resulting from the research on Chinese materia medica pursuant to Chinese medical and pharmaceutical theories, traditional experiences, and modern science and technology, including medicinal resources and identification, cultivation, processing, preparation, chemistry, pharmacology, theory of Chinese pharmacy and clinical practice, bencaological study. The journal is included in CA, JST and CSCD.
Zhang Boli, Hu Zhibi, Yao Xinsheng, Li Lianda, Li Dapeng, Yang Baofeng, Zhou Chaofan, Huang Luqi, Chen Shilin, Li He.
Executive Editorial Board
Cai Shaoqing, Chen Shilin
Molecular mechanism of Puerariae Lobatae Radix in treatment of hepatocellular carcinoma based on network pharmacology
China Journal of Chinese Materia Medica,2020,Vol 45,No. 17
To investigate the potential mechanism of Puerariae Lobatae Radix in the treatment of hepatocellular carcinoma (HCC) by network pharmacology and in vitro cell experiment. The main active components of Puerariae Lobatae Radix and their predicted targets were obtained from TCMSP, and the disease targets were obtained from GeneCards database. The disease and drug prediction targets were intersected to select the common potential therapeutic targets. The “compound-target-disease” network diagram was constructed in Cytoscape 3.7.1, and the common targets were input into the STRING database to build the PPI network. GO function and KEGG pathway enrichment analysis on effective targets were performed by R software. Autodock vina 1.1.2 was used for molecular docking. Finally, the core targets and pathways were preliminarily verified by in vitro experiments. The proliferation of human HCC cells was detected by CCK-8 and EdU enzyme staining, and the expressions of PTEN, PDK1, Akt and GSK3 were detected by Western blot. In this study, 10 components of Puerariae Lobatae Radix (9 components involved in HCC-related targets and signaling pathways), 149 HCC-related targets, and 156 signaling pathways were screened out. The results of network analysis indicated that Puerariae Lobatae Radix may play an anti-HCC effect on key targets, such as Akt, IL6, MAPK3, EGFR, and key pathways, such as PI3K-Akt. The results of molecular docking indicated that puerarin, genistein and daidzein had good binding abilities with the key targets such as AKT1, MAPK3, MAPK1 and CASP3, and puerarin had the lowest Vina score with AKT1 and MAPK3 and also similar to them. In vitro cell experiments confirmed that puerarin had a significantly inhibitory effect on the proliferation of human HCC cells. Western blot results showed that puerarin could increase the phosphorylation of PTEN in human HCC cells through the PTEN/Akt/GSK3 β signaling pathway, and the phosphorylation level of its downstream Akt decreased. This series of studies confirm that puerarin can treat HCC by blocking PTEN/Akt/GSK3 β cellular signaling pathway, so as to provide ideas for subsequent studies for the molecular mechanism of puerarin in the treatment of liver cancer.